The aim of the present study was to find out whether a blockade of
adenosine A2A receptors by the selective antagonist,
SCH 58261, potentiates the attenuating effect of
L-DOPA, the well-known antiparkinsonian drug, on parkinsonian-like
muscle rigidity in rats. Muscle tone was examined using a combined mechano- and electromyographic method, which simultaneously measured muscle resistance of a rat hindfoot to passive extension and flexion in the ankle joint and the electromyographic (EMG) activity of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.
Muscle rigidity was produced by
reserpine (5 mg/kg ip) injected in combination with
alpha-methyl-p-tyrosine (alpha-MT, 250 mg/kg ip).
L-DOPA (25 mg/kg ip) or
SCH 58261 (0.1 mg/kg ip) administered separately, slightly influenced the
reserpine + alpha-MT-induced
muscle rigidity. However, only ankle joint extension was affected significantly while the effect on flexion of the rat hindfoot was not significant. Neither
L-DOPA nor
SCH 58261 given separately modified the
reserpine-enhanced tonic or reflex EMG activities in both muscles examined. However, when
L-DOPA (25 mg/kg) was given together with
SCH 58261 (0.1 mg/kg), a clear synergistic effect was seen on both examined movements and muscles. The present results show that the blockade of
adenosine A2A receptors potentiates the antiparkinsonian effect of
L-DOPA. Since such an effect was seen in different animal models of
Parkinson's disease (PD), it seems that co-administration of
SCH 58261 may allow for the lowering of the doses of
L-DOPA in clinical practice, which indicates a potential therapeutic value of this compound in the treatment of PD.